Journal: International Journal of Molecular Medicine
Article Title: Targeting of CIRP attenuates osteoarthritis progression via suppressing TLR4/NF-κB/NLRP3 signaling axis
doi: 10.3892/ijmm.2025.5674
Figure Lengend Snippet: CIRP secretion in OA human chondrocytes via exosomes. (A) Morphology of exosomes observed using transmission electron microscopy. (B) Particle size distribution of exosomes measured by nanoparticle tracking analysis. (C) Western blotting analysis showing the expression of the exosomal markers CD63, CD9 and GM130 in both cells and exosomes. (D and E) Western blotting showing the protein expression of CIRP in exosomes. (F) Quantitative PCR analysis showing the mRNA expression of CIRP in chondrocytes treated with IL-1β. (G and H) Western blotting analysis showing the protein expression of CIRP in chondrocytes treated with IL-1β. (I) Western blotting analysis showing the protein expression of CIRP in chondrocytes following treatment with the exosome release inhibitor GW4869. (n=3), * P<0.05, *** P<0.001. CIRP, cold-inducible RNA-binding protein; OA, osteoarthritis
Article Snippet: TLR4 inhibitor TAK-242 was purchased from Shanghai Xianding Biotechnology Co., Ltd. Primary antibodies directed against inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), MMP1, MMP3, MMP13, Lamin B1, CD63, CD9, 130 kDa cis-Golgi matrix protein 1 (GM130) and GAPDH were purchased from Proteintech Group, Inc., ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) was purchased from ABclonal.
Techniques: Transmission Assay, Electron Microscopy, Western Blot, Expressing, Real-time Polymerase Chain Reaction, RNA Binding Assay